Avicularin inhibits cell proliferation and induces cell apoptosis in cutaneous squamous cell carcinoma

Wang,Yan; Liu,Mingzhu; Chen,Shenglan; Wu,Qin

doi:10.3892/etm.2019.8303

Avicularin inhibits cell proliferation and induces cell apoptosis in cutaneous squamous cell carcinoma

Authors:
- Yan Wang
- Mingzhu Liu
- Shenglan Chen
- Qin Wu
View Affiliations

Affiliations: College of Medical Technology, Jiangsu Vocational College of Medicine, Yancheng, Jiangsu 224000, P.R. China, Department of Dermatology, Nanjing Integrated Traditional Chinese and Western Medicine Hospital Affiliated to Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210014, P.R. China
Published online on: December 9, 2019 https://doi.org/10.3892/etm.2019.8303
Pages: 1065-1071
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Avicularin (AL), quercetin‑3‑α‑L‑arabinofuranoside, has various pharmacological properties such as anticancer and anti‑infective effects. However, the potential molecular mechanism via which AL exerts its anticancer activity is not fully understood. Cutaneous squamous cell carcinoma (CSCC) is the second most common skin cancer, where metastasis has resulted in in effective clinical treatments. The aim of the present in vitro study was to investigate the anticancer effects and underlying mechanism of AL on human CSCC. The present results suggested that AL dose‑dependently inhibited SCC13 cell viability and induced apoptosis. In addition, the present results suggested that AL induced apoptosis via repression of the mitogen‑activated protein kinase kinase (MEK)/NF‑κB signal pathway, thereby affecting the expression of apoptosis‑related genes. Bax expression level was increased, while Bcl‑2 expression level was decreased in SCC13 cells following AL treatment. In addition, the MEK/NF‑κB signaling pathway‑related genes p‑MEK and phosphorylated‑p65 were also decreased. The present results suggested that AL treatment increased the expression level of E‑cadherin, but decreased the expression levels of N‑cadherin, matrix metalloproteinase (MMP)‑9 and vimentin in SCC13 cells. Collectively, the present results suggested that AL may have an anti‑CSCC effect by inhibiting cell viability, inducing apoptosis and inhibiting epithelial‑mesenchymal transition (EMT) of CSCC cells. The mechanism of these anti‑CSCC effects was suggested to be via the regulation of apoptosis‑related genes and EMT‑related genes, and the inhibition of the MEK/NF‑κB signaling pathway.

View Figures

View References

1	McGuire JF, Ge NN and Dyson S: Nonmelanoma skin cancer of the head and neck I: Histopathology and clinical behavior. Am J Otolaryngol-Head Neck Med Surg. 30:121–133. 2009.
2	Martinez JC and Cook JL: High-risk cutaneous squamous cell carcinoma without palpable lymphadenopathy: Is there a therapeutic role for elective neck dissection? Dermatol Surg. 33:410–420. 2007. View Article : Google Scholar : PubMed/NCBI
3	Weinberg AS, Ogle CA and Shim EK: Metastatic cutaneous squamous cell carcinoma: An update. Dermatol Surg. 33:885–899. 2007. View Article : Google Scholar : PubMed/NCBI
4	Venables ZC, Nijsten T, Wong KF, Autier P, Broggio J, Deas A, Harwood CA, Hollestein LM, Langan SM, Morgan E, et al: Epidemiology of basal and cutaneous squamous cell carcinoma in the U.K. 2013–15: A cohort study. Br J Dermatol. 181:474–482. 2019. View Article : Google Scholar : PubMed/NCBI
5	Trakatelli M, Ulrich C, Del Marmol V, Euvrard S, Stockfleth E and Abeni D: Epidemiology of nonmelanoma skin cancer (NMSC) in Europe: Accurate and comparable data are needed for effective public health monitoring and interventions. Br J Dermatol. 156:1–7. 2007. View Article : Google Scholar : PubMed/NCBI
6	Alam M and Ratner D: Cutaneous squamous-cell carcinoma. N Engl J Med. 344:975–983. 2001. View Article : Google Scholar : PubMed/NCBI
7	Langer CJ: Targeted therapy in head and neck cancer: State of the art 2007 and review of clinical applications. Cancer. 112:2635–2645. 2008. View Article : Google Scholar : PubMed/NCBI
8	Argiris A, Karamouzis MV, Raben D and Ferris RL: Head and neck cancer. Lancet. 371:1695–1709. 2008. View Article : Google Scholar : PubMed/NCBI
9	Trodello C, Pepper JP, Wong M and Wysong A: Cisplatin and cetuximab treatment for metastatic cutaneous squamous cell carcinoma: A systematic review. Dermatol Surg. 43:40–49. 2017. View Article : Google Scholar : PubMed/NCBI
10	Yang L, Wu S, Zhang Q, Liu F and Wu P: 23,24-Dihydrocucurbitacin B induces G2/M cell-cycle arrest and mitochondria dependent apoptosis in human breast cancer cells (Bcap37). Cancer Lett. 256:267–278. 2007. View Article : Google Scholar : PubMed/NCBI
11	Buqui GA, Gouvea DR, Sy SK, Voelkner A, Singh RS, da Silva DB, Kimura E, Derendorf H, Lopes NP and Diniz A: Pharmacokinetic evaluation of avicularin using a model-based development approach. Planta Med. 81:373–381. 2015. View Article : Google Scholar : PubMed/NCBI
12	Fujimori K and Shibano M: Avicularin: A plant flavonoid, suppresses lipid accumulation through repression of C/EBPα-activated GLUT4-mediated glucose uptake in 3T3-L1 cells. J Agric Food Chem. 6:5139–5147. 2013. View Article : Google Scholar
13	Vo VA, Lee JW, Chang JE, Kim JY, Kim NH, Lee HJ, Kim SS, Chun W and Kwon YS: Avicularin inhibits lipopolysaccharide-induced inflammatory response by suppressing ERK phosphorylation in RAW 264.7 macrophages. Biomol Ther. 20:5322012. View Article : Google Scholar
14	Zhang WM, Li RF, Sun M, Hu DM, Qiu JF and Yan YH: UPLC-MS/MS method for determination of avicularin in rat plasma and its application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 965:107–111. 2014. View Article : Google Scholar : PubMed/NCBI
15	Zhu X, Ouyang W, Miao J, Xiong P, Feng K, Li M, Cao Y and Xiao H: Dietary avicularin alleviated type 2 diabetes in mice. FASEB J. 31:46–47. 2017.
16	Srivastava S, Somasagara RR, Hegde M, Nishana M, Tadi SK, Srivastava M, Choudhary B and Raghavan SC: Quercetin, a natural flavonoid interacts with DNA, arrests cell cycle and causes tumor regression by activating mitochondrial pathway of apoptosis. Sci Rep. 6:240492016. View Article : Google Scholar : PubMed/NCBI
17	Wang W, Zheng H, Zheng M, Liu X and Yu J: Protective effect of avicularin on rheumatoid arthritis and its associated mechanisms. Exp Ther Med. 16:5343–5349. 2018.PubMed/NCBI
18	Ghasemzadeh A and Ghasemzadeh N: Flavonoids and phenolic acids: Role and biochemical activity in plants and human. J Med Plants Res. 5:6697–6703. 2011.
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
20	Schenk RL, Strasser A and Dewson G: BCL-2: Long and winding path from discovery to therapeutic target. Biochem Biophys Res Commun. 482:459–469. 2017. View Article : Google Scholar : PubMed/NCBI
21	Sharififar F, Dehghn-Nudeh G and Mirtajaldini M: Major flavonoids with antioxidant activity from Teucrium polium L. Food Chem. 112:885–888. 2009. View Article : Google Scholar
22	Panche AN, Diwan AD and Chandra SR: Flavonoids: An overview. J Nutr Sci. 5:e472016. View Article : Google Scholar : PubMed/NCBI
23	Suematsu N, Hosoda M and Fujimori K: Protective effects of quercetin against hydrogen peroxide-induced apoptosis in human neuronal SH-SY5Y cells. Neurosci Lett. 504:223–227. 2011. View Article : Google Scholar : PubMed/NCBI
24	Ahn J, Lee H, Kim S, Park J and Ha T: The anti-obesity effect of quercetin is mediated by the AMPK and MAPK signaling pathways. Biochem Biophys Res Commun. 373:545–549. 2008. View Article : Google Scholar : PubMed/NCBI
25	Cotter TG: Apoptosis and cancer: The genesis of a research field. Cancer. 9:501–507. 2009.PubMed/NCBI
26	Wong RS: Apoptosis in cancer: From pathogenesis to treatment. J Exp Clin Cancer Res. 30:872011. View Article : Google Scholar : PubMed/NCBI
27	Kim H, Tu HC, Ren D, Takeuchi O, Jeffers JR, Zambetti GP, Hsieh JJ and Cheng EH: Stepwise activation of BAX and BAK by tBID, BIM, and PUMA initiates mitochondrial apoptosis. Mol Cell. 36:487–499. 2009. View Article : Google Scholar : PubMed/NCBI
28	Leverson JD, Phillips DC, Mitten MJ, Boghaert ER, Diaz D, Tahir SK, Belmont LD, Nimmer P, Xiao Y, Ma XM, et al: Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci Transl Med. 7:279ra402015. View Article : Google Scholar : PubMed/NCBI
29	Han L, Zhang EB, Yin DD, Kong R, Xu TP, Chen WM, Xia R, Shu YQ and De W: Low expression of long noncoding RNA PANDAR predicts a poor prognosis of non-small cell lung cancer and affects cell apoptosis by regulating Bcl-2. Cell Death Dis. 6:e16652015. View Article : Google Scholar : PubMed/NCBI
30	van der Noord VE, McLaughlin RP, Smid M, Foekens JA, Martens JWM, Zhang Y and van de Water B: An increased cell cycle gene network determines MEK and Akt inhibitor double resistance in triple-negative breast cancer. Sci Rep. 9:133082019. View Article : Google Scholar : PubMed/NCBI
31	Lawrence T: The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol. 1:a0016512009. View Article : Google Scholar : PubMed/NCBI